ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2077

A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis

Elaine Bell1, Marinella Calle2 and Iain McInnes3, 1Medscape Global Education, London, United Kingdom, 2MEDSCAPE GLOBAL, London, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom

Meeting: ACR Convergence 2023

Keywords: education, medical, Psoriatic arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2061–2088) Professional Education Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) are challenging conditions for rheumatologists to manage. There is an increasing focus on virtual training modalities post-pandemic. We assessed whether a curriculum of online educational activities could improve rheumatologists’ knowledge, competence and confidence in managing patients with spondyloarthritis.

Methods: A curriculum of virtual activities was developed on the evolving therapeutic landscape in the treatment of psoriasis (PSO) and spondyloarthritis (SpA). Data presented here are from the initial 4 activities on SpA, including 2 on line panel discussions and enduring versions of symposia from EADV 2022 and ACR 2022. Data were collected between 2022 and 2023 with n numbers for each activity ranging from 108 to 549 completing pre- and post-activity questions. Educational effect was assessed with a repeated-pairs pre-/post-assessment; 3 multiple-choice, knowledge or competence questions and 1 self-efficacy, 5-point Likert scale confidence question were analyzed. Data were subsequently combined and analyzed by 5 themes to provide a summative overview of the effect of the education across the combined activities. A McNemar’s test was conducted to assess statistical significance of changes from pre- to post-assessment.

Results:

  • 12,256 MD learners across the globe participated in the activities including 3,877 rheumatologists, 3,180 dermatologists and 4,104 primary care physicians
  • Rheumatologists demonstrated a statistically significant improvement in knowledge or competence across 4 of the 5 learning themes (clinical data informing disease management, individualizing treatment to limit disease progression, monitoring disease activity and treatment goals for PsA and axSpA; all P < 0.01)
  • Overall, 79% of rheumatologists gained competence and 26% gained knowledge
  • Overall, 33% of rheumatologists reported increased confidence e.g. in setting appropriate treatment goals or implementing a treat-to-target strategy: for confidence questions aligned with each individual activity, the percentage of rheumatologists who gained confidence ranged from 19% to 59%

Conclusion: These results highlight the benefits of an on-line curriculum of education in challenging rheumatologists to better manage patients with PsA and axSpA. As the treatment landscape for these diseases continues to evolve, rheumatologists will likely benefit from further innovative educational modalities on key clinical data for emerging medicines and strategies for their deployment in clinical practice.


Disclosures: E. Bell: None; M. Calle: None; I. McInnes: AbbVie, 2, Amgen, 2, AstraZeneca, 2, Bristol Myers Squibb, 2, 5, Cabaletta, 2, 11, Causeway Therapeutics, 2, 11, Celgene, 2, 5, Compugen, 2, 11, Dextera, 11, Eli Lilly, 2, EveloBio, 1, 2, 4, 11, Gilead, 2, Janssen, 2, 5, Moonlake, 2, NHS GGC, 4, Novartis, 2, 5, Pfizer, 2, Sanofi, 2, UCB, 2, 5, Versus Arthritis, 12, Trustee Status.

To cite this abstract in AMA style:

Bell E, Calle M, McInnes I. A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/a-curriculum-of-online-education-significantly-improved-rheumatologists-knowledge-competence-and-confidence-in-managing-patients-with-spondyloarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-curriculum-of-online-education-significantly-improved-rheumatologists-knowledge-competence-and-confidence-in-managing-patients-with-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology